{"organizations": [], "uuid": "d4b671a1de92c3e3495f0846fe4708ec66ea9099", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-beigene-initiates-global-phase-2-t/brief-beigene-initiates-global-phase-2-trial-of-anti-pd-1-antibody-tislelizumab-in-patients-with-previously-treated-hepatocellular-carcinoma-idUSASC09VDE", "country": "US", "domain_rank": 408, "title": "BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T14:31:00.000+03:00", "replies_count": 0, "uuid": "d4b671a1de92c3e3495f0846fe4708ec66ea9099"}, "author": "", "url": "https://www.reuters.com/article/brief-beigene-initiates-global-phase-2-t/brief-beigene-initiates-global-phase-2-trial-of-anti-pd-1-antibody-tislelizumab-in-patients-with-previously-treated-hepatocellular-carcinoma-idUSASC09VDE", "ord_in_thread": 0, "title": "BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-beigene initiates global phase", "sentiment": "negative"}, {"name": "beigene ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "previously treated hepatocellular carcinoma reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News  32 AM / Updated 6 minutes ago BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD 1 Antibody Tislelizumab In Patients With Previously Treated Hepatocellular Carcinoma Reuters Staff 1 Min Read \nApril 10 (Reuters) - Beigene Ltd: \n* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED HEPATOCELLULAR CARCINOMA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T14:31:00.000+03:00", "crawled": "2018-04-10T14:45:30.031+03:00", "highlightTitle": ""}